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Background-—Our dual aims were as follows: (1) to classify new or recurrent myocardial infarctions (MI) in patients with stable
atherosclerosis using the Universal Definition of MI classification system; and (2) to characterize the effects of vorapaxar, a first-in-
class platelet protease-activated receptor -1 antagonist, on new or recurrent MI.
Methods and Results-—We analyzed data from TRA 2°P-TIMI 50, a multinational, randomized, double-blind, placebo-controlled trial
of vorapaxar. This analysis included 20 770 patients with previous MI or peripheral arterial disease without a history of transient
ischemic attack or stroke. Each new or recurrent MI after randomization that met the trial end point definition was further
categorized according to the European Society of Cardiology, American College of Cardiology, American Heart Association, World
Heart Federation Universal Definition classification of type and size. Of 1095 incident MIs, 77% were spontaneous (Type 1), with a
smaller number (9.8%) of secondary MIs (Type 2). Vorapaxar reduced Type 1 MI (hazard ratio [HR] 0.84, CI 0.73–0.98, P=0.024),
with a similar pattern for Type 2 MI (HR 0.74, CI 0.49–1.10, P=0.13). Notably, vorapaxar showed a consistent pattern of reduction
across size of MIs, including MIs in the highest Universal MI size class (≥109 upper reference limit, HR 0.83, CI 0.70–0.98,
P=0.025). As such, there was a significant reduction in larger, spontaneous MIs (Type 1, ≥109 upper reference limit, HR 0.81, CI
0.67–0.99, P=0.036), and a consistent pattern with respect to fatal MI (HR 0.66, CI 0.39–1.11, P=0.12).
Conclusions-—Among stable patients with established atherosclerosis, the most common type of incident MI is spontaneous MI,
and the reduction in MI with vorapaxar was consistent across MIs of varying type and size, including spontaneous infarctions ≥109
upper reference limit.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identifier: NCT00526474. ( J Am Heart Assoc. 2016;5:
e003237 doi: 10.1161/JAHA.116.003237)
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V orapaxar is a first-in-class protease-activated receptor-1 receptor antagonist that is effective for long-term
secondary prevention in patients with stable atherosclerosis
without a history of stroke or transient ischemic attack.1,2
Vorapaxar reduces the risk of recurrent thrombotic events
in this population, decreasing the incidence of recurrent
myocardial infarction (MI) in particular.1 Further character-
ization of the types, sizes, and consequences of MI that
may be reduced with vorapaxar may be useful for informing
clinicians weighing the ischemic benefits against increases
in bleeding with additional, more potent antithrombotic
therapy.3
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ORIGINAL RESEARCH
Therefore, we performed an additional classification of the
MI end points in the Thrombin Receptor Antagonist in
Secondary Prevention of Atherothrombotic Ischemic Events
(TRA 2°P)-TIMI 50 trial1 using the classification system from
the European Society of Cardiology, American College of Car-
diology, American Heart Association, World Heart Federation
(ESC/ACC/AHA/WHF) Universal Definition of MI4,5 with 2
objectives: (1) to characterize new or recurrent MI in patients
with stable atherosclerosis, and delineate their type and
size4,5; and (2) to characterize more completely the effects of




The study design and primary results of the TRA 2°P-TIMI 50
trial have been published previously.1,6 TRA 2°P-TIMI 50 was a
multinational, randomized, double-blind, placebo-controlled
trial of vorapaxar in 26 449 patients with prior MI, ischemic
stroke, or peripheral arterial disease (PAD). The complete
eligibility criteria for the trial have been described in detail.1,6
Vorapaxar has been approved in the United States and Europe
for clinical use in patients with prior MI, and in the United States
also for use in patients with PAD, but is contraindicated in all
existing labels in patients with a history of transient ischemic
attack or stroke.2 Therefore, we performed the present analysis
among the 20 770 patients without a known cerebrovascular
event prior to randomization in the trial. Eligible patients had a
history of stable atherosclerosis, defined as a spontaneous MI
within the 2 weeks to 12 months preceding randomization or
symptomatic PAD.1,6 Patients were ineligible for the trial if they
were clinically unstable, or planning to undergo a revascular-
ization procedure that had yet to be performed. Sensitivity
analyses designed to assess the impact of the timing of
randomization relative to a qualifying MI were performed and
are described in Statistical Methods. The study protocol was
approved by all relevant institutional review boards, and written
informed consent was obtained from all patients.
End Points
All end points, including MI, were adjudicated according to the
prespecified trial definitions by an independent Clinical
Endpoints Committee that was blinded to treatment assign-
ment. Local creatine kinase MB and cardiac troponin data
were collected for suspected ischemic events throughout the
study period. Potential myocardial ischemic events were
identified through reporting by the investigator and program-
matic checks of biomarker data.1 Each Clinical Endpoints
Committee–determined MI underwent a supplemental
classification according to the ESC/ACCF/AHA/WHF Univer-
sal Definition classification of MI type4,5 into 1 of the following
categories: spontaneous (Type 1); ischemic imbalance (Type
2); death without biomarker data available (Type 3); MI related
to percutaneous coronary intervention (Type 4); and MI
related to coronary artery bypass grafting (Type 5). Source
narratives, progress notes, discharge summaries, and labora-
tory and electrocardiographic data were reviewed for clear
evidence of a secondary cause of MI (eg, arrhythmia, profound
anemia, or severe hypertension) prior to defining a nonpro-
cedural MI as Type 1 or Type 2. Periprocedural (Type 4a) MI
was defined as an increase of more than 39 the 99th
percentile of cardiac biomarker. If the pre–percutaneous
coronary intervention biomarker was greater than the upper
reference limit (URL), both an increase by at least 50% over
the previous value and documentation that the biomarker was
decreasing prior to the suspected recurrent MI were
required.1,6 A sensitivity analysis was performed using a 59
URL threshold for Type 4a MI introduced in the 3rd Universal
Definition after TRA 2°P-TIMI 50 began. Type 4b MI was
defined as a MI associated with stent thrombosis as
documented by angiography or at autopsy.
In addition, each new or recurrent MI was categorized by
size based on peak biomarker concentration, preferentially
utilizing cardiac troponin over creatine kinase MB when both
were available, in multiples of the 99th percentile URL
according to the Universal Definition classification system.4,5
Cardiac troponin was available in 94% of patients. Details of
each local assay manufacturer and platform were not
collected in this trial and, therefore, the URL was defined by
the MI limit reported by the local laboratory. We have
previously published the full details of incident stent throm-
bosis in this population7 and thus for the purpose of the
current report, we present data focused on Type 1 and Type 2
MI. For the purpose of the present analysis, an MI was
classified as fatal if the patient died within 30 days of the MI.
Statistical Methods
Efficacy analyses were performed using a Cox proportional-
hazards model, with the investigational treatment allocation,
qualifying atherosclerosis (MI or PAD), and planned use of a
thienopyridine as covariates. Cumulative event rates at 3 years
were calculated by the Kaplan–Meier method. All patients
contributed to the survival analyses through their final clinical
event assessment, death, or withdrawal of consent, whichever
occurred first. Efficacy data were analyzed on an intention-to-
treat basis. Analyses of each MI type and size category were
conducted using the time to the first MI in that category. In
order to assess whether there was an impact on the timing of
the qualifying MI relative to enrollment on the epidemiology of
the types of recurrent MI, we performed 2 sensitivity analyses
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of the distribution of MI type over time: (1) We examined the
distribution of the Universal Classification Type of new/
recurrent MIs within groups defined by the time from the
qualifying MI (<3, 3–6, >6 months); and (2) We assessed the
distribution of MI type in a landmark analysis starting at
12 months after randomization in the trial. Safety analyses
were performed among patients who received 1 or more doses
of study drug and included events through 60 days after
premature cessation of study therapy or 30 days after a final
visit at the conclusion of the trial.
The risk of cardiovascular death was analyzed utilizing Cox
regression with a landmark analysis starting at the time of a
new or recurrent MI through 2 years after such an MI or
starting at the time of randomization for those without an MI
end point. This analysis was performed adjusting for covari-
ates related to both incident MI and cardiovascular death,
including age, hypertension, diabetes, hypercholesterolemia,
smoking status, prior coronary revascularization, prior MI,
peripheral arterial disease, congestive heart failure, chronic
kidney disease (CrCl <60 mL/min), and planned thienopy-
ridine at baseline. Analyses were performed using Stata v14.1
(Stata Corp., College Station, TX).
Results
Among the 20 770 patients included in this analysis, 1095
incident MIs of known type and size occurred during a median
follow-up of 30 months (Figure 1). There was 1 Type 3 and 1
Type 5 MI, which, given their rarity, are not characterized in
further detail in this report. The majority of incident MIs
(n=918, 84%) were in patients who qualified for the trial with a
history of MI. Among patients with an incident MI after
randomization, 132 patients had multiple MIs, accounting for
an additional 203 of the 1095 MIs.
The baseline characteristics for the population studied in
this analysis are shown in the Table. Patients with incident MI
were more likely to have a history of congestive heart failure
and diabetes mellitus. Aspirin use was consistent between
cohorts and there was a slightly higher rate of thienopyridine
use in patients with incident MI.
Type and Size of New or Recurrent MI
The annualized rate of any new or recurrent MI after trial
enrollment was 2% per year. The distribution of MIs according
to MI type and size is shown in Figure 2. The majority of new
or recurrent MIs were spontaneous (Type 1, n=842, 77%), with
a smaller number of secondary MIs (Type 2, n=107, 9.8%) or
procedurally related MIs (Type 4, n=144, 13%), of which only
15 (1.4%) were Type 4a MIs. Most MIs were non-ST elevation
MIs (NSTEMIs) (n=732, 81%) and were of the largest Universal
MI size category ≥109 URL (n=645, 59%), followed by 5 to
<109 URL (n=158, 14%). Among the 19% of MIs that were
STEMIs, 84% were in the largest size category. Of the Type 4a
26,449 paents enrolled
in TRA 2°P-TIMI 50
20,770 paents without 
history of stroke/TIA
1,095 MIs of known type and size
among 892 paents
918 MIs in 8,898 paents 
with history of MI
177 MIs in 1,892 paents 
with history of PAD
• 760 pts with a single MI post-randomizaon 
• 132 pts with mulple MIs (335 MI events)
Limit to paents without
Contraindicaon (stroke or TIA)
Figure 1. Flow diagram of myocardial infarctions included in the
analysis. MI indicates myocardial infarction; PAD, peripheral arterial









Median, y (25th, 75th) 62 (54, 70) 60 (52, 67)
≥75 y 139 (15.6) 1699 (8.9)
Female 214 (24.0) 4123 (21.6)
White race 785 (88.0) 16 951 (88.7)
Qualifying atherosclerosis, n (%)
Myocardial infarction 749 (84.0) 16 018 (83.7)
Peripheral arterial disease 143 (16.0) 3113 (16.3)
Clinical characteristics, n (%)
Diabetes mellitus 324 (36.3) 4392 (23.0)
Hypertension 687 (77.1) 12 291 (64.2)
Hyperlipidemia 811 (90.9) 16 192 (84.6)
Current smoker 226 (25.3) 4103 (21.4)
Previous coronary
revascularization
738 (82.7) 15 049 (78.7)
Congestive heart failure 162 (18.2) 1547 (8.1)
Antiplatelet agents at randomization, n (%)
Thienopyridine 684 (76.7) 13 594 (71.1)
Aspirin 853 (95.6) 18 508 (96.7)
MI indicates myocardial infarction.
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MIs, only 1 had a peak concentration between <59 URL. In an
analysis of MI size using only creatine kinase MB data, 29% of
MIs were associated with peak creatine kinase MB ≥109 URL
(n=128) and 57% were ≥39 URL. Among patients who had
qualified for the trial with a prior MI, the distribution of type
and size of incident MIs was remarkably consistent across
groups defined by the time from a qualifying MI to study
enrollment (Figure 3).
Mortality After New or Recurrent MI
In an adjusted landmark analysis, compared to those without
incident MI, patients with an incident MI had a significantly
higher risk of cardiovascular death over the ensuing 2 years
(hazard ratio [HR] 7.8, CI 6.0–10.1). This heightened risk of
cardiovascular mortality was present for patients with a Type
1 MI (HR 7.4, CI 5.6–9.9), and for those with secondary (Type
2) MIs (Figure 4). In this population in which Type 4 MIs were
predominantly due to stent thrombosis, Type 4 MI was
associated with higher cardiovascular mortality. There were
an insufficient number of Type 4a MIs to assess the
relationship with mortality. In a sensitivity analysis using all-
cause mortality as the outcome, patients with an incident MI
had a similarly increased risk of death from any cause (HR
6.62, CI 5.35–8.21) that was consistent across the types and
sizes of MI. Interestingly, a higher risk of cardiovascular death
was apparent for patients not only with MIs in the higher
Universal MI size classes (≥109 URL, HR 9.1, CI 6.8–12.2;
5–<109 URL, HR 6.7, CI 3.6–12.3) but also those patients
with a smaller incident MI (1≤39 URL; HR 9.6, CI 6.2–15.0).
Effect of Vorapaxar
Compared with placebo, vorapaxar significantly reduced the
incidence of overall MI with a consistent pattern of reduction
across MI of each type (Figure 5). Specifically, vorapaxar
reduced spontaneous MI (Type 1, HR 0.84, CI 0.73–0.98,
P=0.024; Figure 6A), with a similar pattern for secondary MI
(Type 2, HR 0.74, CI 0.49–1.10, P=0.13). The reduction in
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Figure 2. Distribution of incident MIs classified according to the
universal MI classification system of type and size. There were a
total of 190 STEMI and 732 NSTEMI. Type 4 MIs were dominated
by Type 4b with only 15 Type 4a MIs. MI indicates myocardial
infarction; NSTEMI, non-ST-segment elevation myocardial infarc-









































































MI Size (x URL)Type of MI
Landmark AnalysisLandmark Analysis
MI Type MI Size
Figure 3. Distribution of MI type and size by time from qualifying MI to study enrollment (first 3 bars). The 4th bar in each panel is from a
landmark analysis starting at 1 year after enrollment for all subjects. MI indicates myocardial infarction.
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ST-segment elevation MIs (HR 0.81, CI 0.61–1.07) and non-
ST-segment elevation MIs (HR 0.83, CI 0.72–0.96).
When considering MI size, vorapaxar reduced MIs in the
highest Universal MI size class (≥109 URL, HR 0.83, CI 0.70–
0.98, P=0.025; Figure 6B). Importantly, there was a signifi-
cant reduction in these larger, spontaneous MIs (Type 1,
≥109 URL, HR 0.81, CI 0.67–0.99, P=0.036), and a
consistent pattern with respect to fatal MI (HR 0.66, CI
0.39–1.11, P=0.12).
An exploratory analysis of net clinical outcomes limiting
incident MI to those that were spontaneous or >109 URL
revealed a more favorable outcome with vorapaxar;
cardiovascular death, Type 1 MI, stroke, or Global Utilization
of Streptokinase and Tissue Plasminogen Activator for
Occluded Arteries (GUSTO) severe bleeding: HR 0.83, CI
0.74–0.92, P=0.001; and cardiovascular death, MI with peak
biomarker ≥109 URL, stroke, GUSTO severe bleed: HR 0.83,
0.74–0.93, P=0.001.
Discussion
In this analysis of an international trial conducted at 1032
sites including 20 770 stable patients with prior MI or








































Hazard Ratio for CV Mortality
10
Figure 4. Risk of cardiovascular death following an incident MI compared with those
without incident MI stratified by MI type and size. There was a consistent risk of CV death
after both STEMI (HR 11.6, CI 6.7–20.1) and NSTEMI (HR 7.4, CI 5.6–9.8). CV indicates
cardiovascular; HR, hazard ratio; MI, myocardial infarction; NSTEMI, non-ST-segment
elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
Figure 5. Effect of vorapaxar on incident MI stratified by universal MI type and size. This
analysis is based on the first MI of each given type or size. HR indicates hazard ratio; MI,
myocardial infarction.
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follow-up, we found that Type 1 MI was the predominant type
of incident MI and that most such MIs were associated with
>10-fold elevation of cardiac biomarkers of necrosis. Although
other types of MI were less frequent, Type 2 MI accounted for
almost 10% of incident MIs. Type 4a MIs were very
uncommonly detected in this stable population with estab-
lished atherosclerosis. Moreover, incident MIs of Type 1, Type
2, or Type 4b were associated with a higher mortality risk in
this population. These findings are relevant to strategies for
secondary prevention of atherothrombosis in these high-risk
patients and establish a rationale for consideration of
additional long-term antithrombotic therapy directed at
reducing thrombotic events. We also found a lower risk of
new or recurrent MI with vorapaxar in this population with a
consistent pattern of effect across MIs of varying type and
size.
Epidemiology of MI in Stable Atherosclerosis
We and others have previously described the epidemiology of
MI using the Universal MI Classification system in patients
presenting with unstable chest symptoms or after presenta-
tion with an acute coronary syndrome.8–11 In these studies,
Type 1 (spontaneous) and Type 4 (procedurally related) MIs
have predominated. For example, in a trial of patients with
ACS undergoing percutaneous coronary intervention, 33% of
new or recurrent MIs were spontaneous and 63% were
procedurally related (Type 4).8 Subsequent analyses revealed
that spontaneous MIs contributed the majority of events after
the initial hospitalization. Type 2 (secondary/demand-related)
MIs accounted for less than 4% of the incident MIs over a 15-
month period. However, with the increasing sensitivity of
assays for cardiac troponin, experts have speculated that
small Type 2 or Type 4a (peri-percutaneous coronary inter-
vention) MI might dominate the epidemiology of incident
MIs.12 Estimates of the incidence of Type 2 MI from previously
published studies are heterogeneous, likely owing to differ-
ences across settings as well as variable definitions of MI and
adjudication processes.13,14
The current study adds to this growing experience. We
found that in this population with symptomatic atherosclero-
sis, most MIs were spontaneous. Notably, in our population of
stable patients who were at least 2 weeks after a prior MI, the
distribution of the types of recurrent MI was very similar
irrespective of whether the patient was <3, 3 to 6, or
>6 months after the preceding MI. In this trial of a medical
therapy among patients with stable atherosclerosis, there
were very few Type 4a MIs detected. Moreover, it is likely that
the clinical criteria incorporated into the 3rd Universal
Definition of Type 4a MI would have only increased the
relative proportion of Type 1 MIs in our cohort. These findings
substantiate spontaneous atherothrombotic events as a
target for secondary prevention in patients with known
coronary and other atherosclerotic vascular disease, who are
well treated with guideline-directed secondary preventive
therapies, with both recent and more remote MI.1,9 However,
at the same time 10% were Type 2, a proportion that is
greater than some previous studies applying the Universal
Definition of MI.13,14 Additionally, the risk of cardiovascular
death was higher among patients with both Type 1 and Type 2
MI. The varying estimates of both incidence and outcomes
associated with Type 2 MI point to the emerging need for well-
designed prospective studies of this population.9
Effect of Vorapaxar
Our findings expand the evidence that vorapaxar is effective in
reducing the risk of new or recurrent MI when used for long-
term secondary prevention in stable patients with established
atherosclerosis. This reduction in MI was observed for both
ST-segment elevation MIs and non-ST-segment elevation MIs,
and was consistent across all sizes of spontaneous MI,
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Spontaneous (Type 1) MI 
Placebo (4.34%)
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Hazard Rao, 0.83 (95% CI, 0.70-0.98)
P=0.025





Figure 6. Kaplan–Meier estimated rates of MIs that were spon-
taneous (A) or in the highest Universal classification system size
class (≥109 URL) (B) with vorapaxar vs placebo. MI indicates
myocardial infarction; URL, upper reference limit.
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that we also observed a consistent pattern of efficacy with
vorapaxar when considering Type 2 MI, a type of myocardial
injury considered to result primarily from a mismatch in
myocardial oxygen delivery (anemia, hypoxemia, etc) and
demand (eg, tachycardia, heart failure) without plaque insta-
bility.5,8,15 In addition to its action on human platelets,
activation of protease activated receptor-1 on other cell types
stimulates recruitment of inflammatory cells, and proliferation
of vascular smooth muscle cells within atherosclerotic
arteries.16 It is possible that the observed reduction in MI
with vorapaxar is mediated, in part, through mechanisms
unrelated to platelet activation. Alternatively, platelet activa-
tion may have a more substantial role in the pathophysiology
of a subset of patients with Type 2 MI than previously thought.
These effects of vorapaxar on thrombotic events must be
clinically weighed against the risk of bleeding as we have
described previously1,2 in developing risk:benefit decisions for
the individual patient.
Limitations
First, the analyses presented in the present report are based on
a subset of the overall cardiovascular end points for which the
trial was powered. Therefore, we have limited power within
smaller subsets of events for individual hypothesis testing (eg,
among Type 2 MIs). Second, although our Clinical Endpoints
Committee is highly experienced with the adjudication of Type
2 MI from previous studies by our group, the adjudication of
Type 2 MI is, at present, inherently dependent on judgment by
blinded adjudicators regarding the plausible contribution of
increased myocardial oxygen demand and the absence of
acute atherothrombosis based on the complete constellation
of diagnostic information available. Third, the worldwide
pattern of use of assays for cardiac troponin is changing as
high sensitivity assays are now used commonly outside of the
United States. Our results reflect the general use of troponin
assays and cut points in practice at the time of the trial.
Growing use of high-sensitivity assays and lower cut points
may increase the proportion of smaller infarctions as well as
Type 2 MIs that are detected. These limitations would not
influence our randomized assessment of the effect of vora-
paxar versus placebo. Future studies will be useful to
characterize the distribution of MI size in the era of high-
sensitivity assays. The trial was not designed with the intent to
provide sufficient power to perform hypothesis testing with
respect to each subtype of MI but rather to examine the
consistency of the estimates of the effect of vorapaxar
compared with the overall result. The sample size for some
individual MI types is therefore small and resulting confidence
limits are wide. In particular, we cannot conclude that there is a
definite effect of vorapaxar on Type 2 MI. Fourth, in contrast to
the comparison between vorapaxar and placebo, the
assessment of the risk of cardiovascular death between
patients with and without incident MI after randomization
(Figure 4) was a nonrandomized analysis and thus we cannot
definitively infer a causal relationship. Despite adjusting for
multiple known potential confounders, it is possible that
unmeasured confounders remain and that the relative risk
associated with MI is smaller in magnitude than estimated in
this study.
Conclusions
Among stable patients with established atherosclerosis, the
most common type of incident MI is spontaneous (Type 1) MI
with peak biomarkers ≥109 URL. Type 2 (demand-related)
MIs appear more common than previously appreciated. The
reduction in MI with vorapaxar was consistent across MIs of
varying type and size, including larger spontaneous infarc-
tions.
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